Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 16 January 2026 - 21 January 2026

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly shares closed up 0.3% at $1,041.29 Tuesday and rose slightly after hours after the FDA granted Breakthrough Therapy status to its ovarian cancer drug candidate, sofetabart mipitecan. The designation targets adults with platinum-resistant ovarian cancer. Analyst Seamus Fernandez maintained a buy rating but trimmed his price target. Abivax’s CEO denied rumors of takeover talks with Lilly.
21 January 2026
·····
Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly shares rose about 0.2% Tuesday after the FDA granted Breakthrough Therapy designation to its experimental ovarian cancer drug, sofetabart mipitecan. The stock traded near $1,040 as the broader market fell 1%. The designation covers patients with platinum-resistant disease who have tried other therapies. Bernstein maintained its Outperform rating and $1,300 price target.
20 January 2026
····
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
····
Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

COPENHAGEN, Jan 18, 2026, 21:16 CET — Market closed. Novo Nordisk A/S Class B shares (NOVOb.CO) surged 6.49% on Friday, closing at 388.9 Danish crowns after hitting a high of 391.3 crowns during the session. The stock is set to reopen Monday, with traders reacting to the latest Wegovy news. (Investing.com) Investors are weighing whether Novo’s once-daily Wegovy pill is gaining traction in the U.S. as the obesity drug market shifts toward a consumer-driven, cash-pay model. IQVIA data revealed 3,071 retail prescriptions filled within the first four days after its Jan. 5 launch. Novo described the “early signs” as positive
18 January 2026
·······
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

New York, January 18, 2026, 10:06 EST — Market closed Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open. Why it matters now: Lilly’s next valuation boost hinges on weight loss, and investors are weighing two fresh signals — the speed of the U.S. drug regulator’s action, and whether pills can expand demand beyond injections. The setup is more delicate than it appears. Speeding up the timeline for a new oral
18 January 2026
······
Merck stock price slips after FDA fast-track questions; what MRK investors watch next week

Merck stock price slips after FDA fast-track questions; what MRK investors watch next week

New York, January 17, 2026, 15:06 (EST) — Market closed Merck & Co (MRK.N) shares dropped 1.9% on Friday, ending the day at $108.83. That’s roughly 4% shy of their 52-week peak of $112.90 hit earlier this month. (Reuters) Investors start the week focused on a new FDA fast-track program targeting quick decisions—just one to two months—on a select group of drugs. Internal documents obtained by Reuters reveal the FDA has already postponed reviews for some medicines chosen for the Commissioner’s National Priority Voucher Program, which promises to shave four to six months off the usual “priority review” timeline. The
17 January 2026
·····
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

NEW YORK, January 17, 2026, 14:16 EST — The market has closed. U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week. (Reuters) U.S. markets are closed Monday for Martin Luther King Jr. Day, giving healthcare investors an extended break before action resumes Tuesday. The sector has fallen behind despite earnings season picking
17 January 2026
··········
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

New York, Jan 17, 2026, 10:03 ET — Market closed. Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication. The key issue now is timing. A postponed verdict on Lilly’s oral weight-loss drug comes amid a rapidly evolving race, where pills aim to expand the market beyond injectable treatments. This matters because the company’s upcoming catalysts come in quick succession, and with the U.S. market reopening Tuesday after a holiday, the stock has limited time to absorb new developments before the next wave
17 January 2026
·····
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Copenhagen, Jan 17, 2026, 10:59 CET — Market closed. Novo Nordisk shares gained 6.5% on Friday, closing at 388.9 Danish crowns, positioning the stock for a notable open Monday. In New York, the company’s ADRs jumped 9.1% to finish at $62.33. (Investing.com) This move is crucial as investors seek confirmation that Novo’s new Wegovy pill will maintain its first-to-market advantage amid growing competition, notably from Eli Lilly’s oral obesity drug. Novo described the “early signs” as positive but cautioned that it’s too soon to draw conclusions about trends for the daily pill. (Reuters) The initial figure was modest but clear:
17 January 2026
·······
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

NEW YORK, Jan 16, 2026, 21:08 EST — Market closed. Shares of Merck & Co (MRK.N) dipped 1.9% Friday, closing at $108.83 following a range of $108.49 to $111.19. The stock kicked off the session at $110.63 with roughly 14.9 million shares traded. The drop came as investors digested a Reuters report revealing some drugmakers’ unease over the FDA Commissioner’s National Priority Voucher Program — a fast-track approval process launched in June that cuts review times to one or two months for select drugs. At the J.P. Morgan Healthcare Conference, executives and advisers warned the accelerated timeline might compromise safety
17 January 2026
·······
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

New York, January 16, 2026, 17:39 EST — After-hours Eli Lilly (LLY.N) shares ticked up about 0.5%, closing at $1,038.40 in after-hours trading Friday, after swinging between $1,019.00 and $1,049.83 during the session. Internal documents reviewed by Reuters revealed the U.S. FDA has pushed back its target decision date for Lilly’s obesity drug orforglipron to April 10. Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, noted the delay signals the agency remains cautious, essentially saying: “Hold on, we’re not actually sure this product should be allowed on the market.” (Reuters) Timing is crucial as Lilly vies
17 January 2026
·····
Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus

Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus

New York, Jan 16, 2026, 11:00 EST — Regular session Eli Lilly shares rose 0.3% to $1,036.46 on Friday morning, after touching as low as $1,019, as investors weighed an updated U.S. regulatory timeline for the company’s experimental obesity pill. (Reuters) The stock has become a proxy for how fast the next wave of weight-loss drugs can move from injections to pills — and whether demand holds up as insurers push back and more patients pay cash. That question is getting louder this week as early U.S. prescription data for Novo Nordisk’s newly launched Wegovy pill begins to circulate among
16 January 2026
···
1 2 3 4 5 6 … 13

Stock Market Today

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

7 February 2026
Rio Tinto’s U.S. shares closed up 2.5% at $93.37 Friday after the company ruled out a merger with Glencore, triggering a six-month “no-bid” lockout under UK takeover rules. Both companies cited disagreements over valuation. Attention now turns to Rio’s Feb. 19 results and iron ore prices, which fell below $100 a tonne amid weak Chinese demand.
iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Go toTop